Virtual Library
Start Your Search
N. Pande
Author of
-
+
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
-
+
165P - Analysis of our experience of ROS-1 patients in advanced NSCLC (ID 518)
12:30 - 13:00 | Presenting Author(s): N. Pande
- Abstract
Background:
ROS1 is a receptor tyrosine kinase receptor and it belongs to insulin receptor family.[1] It acts as a driver oncogene in 1 to 2% of NSCLC patients. A homology exists between ALK and ROS1 Kinase domains. Crizotinib binds with high affinity to both ALK and ROS1, which is consistent with this homology. Crizotinib is approved for patients with the ROS1 translocation including those who have received chemotherapy and those who are treatment naïve. We report our experience in a tertiary cancer care centre in ROS-1 positive patients.
Methods:
Patients who were ROS-1 positive by break-apart Fluorescence In situ Hybridization (FISH) and who had advanced NSCLC being planned treatment with palliative intent were included in our study. We had a total of 22 patients whose details were obtained from the prospective lung cancer audit database that is maintained in the department of medical oncology. Details of patients demographic data (age, gender, comorbidities, smoking status and performance status), tumour characteristics (histology, stage, number and sites of metastases) treatment (crizotinib dose, sequence of treatment, dose interruptions, treatment used before and after crizotinib,) efficacy and side effects were retrieved. Response evaluation done by RECIST 1.1 criteria.
Results:
A total of 22 patients satisfied the predefined selection criteria. There were 13 males and 9 females in this group and the median age of the population was 53 years. 10 patients received Platinum doublet as first line and 1 received Erlotinib as first line in view of poor PS. Six patients could be started on Crizotinib as first line. A total of 16 patients took Crizotinib either in first or second line. The patients who were on Crizotinib had good tolerance with none experiencing any grade 3/4 toxicity. The median follow up was 244 days in non-crizotinib arma and 322 days in Crizotinib arm. The estimated PFS was 79 days in non-crizotinib arm and 573 days in those who received Crizotinib. The estimated OS was 79 days vs not reached in Crizotinib arm.
Conclusions:
In conclusion, crizotinib is effective treatment with acceptable side effect profile in patients with ROS1 rearranged advanced NSCLC with significant improvement in PFS and OS.
Clinical trial identification:
Legal entity responsible for the study:
Nikhil Pande
Funding:
Has not received any funding
Disclosure:
All authors have declared no conflicts of interest.
